Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Vandetanib, added to cisplatin and radiation (RT) overcomes chemo RT and EGFR inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. METHODS: Patients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) then vandet...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Head Neck
मुख्य लेखकों: Papadimitrakopoulou, VA, Frank, SJ, Cohen, EW, Hirsch, FR, Myers, JN, Heymach, JV, Lin, H, Tran, HT, Chen, CR, Jimeno, A, Nedzi, L, Vasselli, JR, Lowe, ES, Raben, D
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414661/
https://ncbi.nlm.nih.gov/pubmed/25352401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23922
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन